Literature DB >> 33796557

Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case.

Claudio Marasca1, Gabriella Fabbrocini1, Luisa Abategiovanni1, Elisa Camela1, Mariateresa Nocerino1, Adriana Di Guida1, Gaia De Fata Salvatores1.   

Abstract

Acne fulminans (AF) is a rare, acute, and severe form of acne vulgaris often associated with systemic symptoms. Its treatment is challenging and controversial. We report a case of isotretinoin-induced AF (IIAF) in a 12-year-old boy resistant to traditional therapies (oral steroids and isotretinoin). The patient was successfully treated with adalimumab that can be considered an effective off-label option in the treatment of resistant IIAF in children.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Acne fulminans; Adalimumab; Isotretinoin; Treatment

Year:  2021        PMID： 33796557      PMCID： PMC7991494          DOI： 10.1159/000512032

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN： 2296-9160


  12 in total

Review 1.  Evidence-based recommendations for the management of acne fulminans and its variants.

Authors:  Tanya Greywal; Andrea L Zaenglein; Hilary E Baldwin; Neal Bhatia; Karen A Chernoff; James Q Del Rosso; Lawrence F Eichenfield; Marc H Levin; James J Leyden; Diane M Thiboutot; Guy F Webster; Sheila Fallon Friedlander
Journal:  J Am Acad Dermatol       Date:  2017-07       Impact factor: 11.527

2.  Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case.

Authors:  Claudio Marasca; Giuseppina Fontanella; Maria C Annunziata; Dario Marasca; Gabriella Fabbrocini
Journal:  Int Wound J       Date:  2019-04-01       Impact factor: 3.315

3.  A dramatic case of acne fulminans responding to adalimumab.

Authors:  Diana Miguel; Jörg Tittelbach; Peter Elsner
Journal:  J Dtsch Dermatol Ges       Date:  2019-05-06       Impact factor: 5.584

4.  Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa.

Authors:  A Balato; G Caiazzo; M C Annunziata; C Marasca; E Scala; S Cacciapuoti; G Fabbrocini
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-07-30       Impact factor: 6.166

Review 5.  Acne fulminans: explosive systemic form of acne.

Authors:  R Zaba; Ra Schwartz; S Jarmuda; M Czarnecka-Operacz; W Silny
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-10-03       Impact factor: 6.166

6.  Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skin.

Authors:  Giuseppe Monfrecola; Serena Lembo; Giuseppina Caiazzo; Valerio De Vita; Roberta Di Caprio; Anna Balato; Gabriella Fabbrocini
Journal:  Exp Dermatol       Date:  2015-12-03       Impact factor: 3.960

7.  Adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapy.

Authors:  Noha Mohammed Dawoud; Basant Mohammed Elnady; Tohamy Elkhouly; Ayman Yosef
Journal:  Indian J Dermatol Venereol Leprol       Date:  2018 Jan-Feb       Impact factor: 2.545

8.  Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.

Authors:  Gerd Horneff; Marieke M B Seyger; Dilek Arikan; Jasmina Kalabic; Jaclyn K Anderson; Andreas Lazar; David A Williams; Chen Wang; Rita Tarzynski-Potempa; Jeffrey S Hyams
Journal:  J Pediatr       Date:  2018-07-25       Impact factor: 4.406

9.  Acne fulminans: report of clinical findings and treatment of twenty-four patients.

Authors:  S L Karvonen
Journal:  J Am Acad Dermatol       Date:  1993-04       Impact factor: 11.527

10.  Acne fulminans.

Authors:  Nelson Guimarães Proença
Journal:  An Bras Dermatol       Date:  2017       Impact factor: 1.896
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.